Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of oral CF101 in elevated intraocular pressure
2011-002777-27Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Glaucoma and ocular hypertension comparing CF101 oral twice daily with Placebo oral twice daily (2 arms). Primary endpoint: Change in intraocular pressure. Started Nov 2011; status: completed.
02
Drugs
piclidenoson
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2011-002777-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002777-27.